The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination

Vaccine

Volumn 29, Issue 22, 2011, Pages 3832-3836

  Parvanova, Iana ^a   Rettig, Lorna ^a   Knuth, Alexander ^a   Pascolo, Steve ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adjuvant; Cancer; NY ESO 1; Vaccination

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NY ESO 1 ANTIGEN; PLASMID DNA; TOLL LIKE RECEPTOR AGONIST; DNA VACCINE; ESO 1 PROTEIN, MOUSE; ESO-1 PROTEIN, MOUSE; HLA ANTIGEN CLASS 2; HOMEODOMAIN PROTEIN; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; TREATMENT OUTCOME; VACCINATION;

ANIMALS; CANCER VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HOMEODOMAIN PROTEINS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 80051739242     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.073     Document Type: Article

References (24)

1. Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol 2007;142(3):179-89.
2. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 2007;25(September (Suppl 2)):B61-71.
3. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006;95:1-30.
4. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60(August (16)):4499-506.
5. Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J Immunother 2009;32(February-March (2)):161-8.
6. Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, et al. HLA class I-associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. Clin Cancer Res 2009;15(January (1)):299-306.
7. Le Gal FA, Ayyoub M, Dutoit V, Widmer V, Jager E, Cerottini JC, et al. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother 2005;28(May-June (3)):252-7.
8. Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 2002;110(December (12)):1813-22.
9. Garcia Casado J, Janda J, WeiJ, Chapatte L, Colombetti S, Alves P, et al. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo. Eur J Immunol 2008;38(July (7)):1867-76.
10. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006;103(September (39)):14453-8.
11. Rettig L, Haen SP, Bittermann AG, von Boehmer L, Curioni A, Kramer SD, et al. Particle size and activation threshold: a new dimension of danger signalling. Blood 2010;(March).
12. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94(March (5)):1914-8.
13. Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 2010;185(September (6)):3768-76.
14. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187(January (2)): 265-70.
15. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010;16(May (10)): 2781-91.
16. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005;35(May (5)): 1557-66.
17. HammS, Heit A, Koffler M, Huster KM, Akira S, Busch DH, et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int Immunol 2007;19(March (3)):297-304.
18. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004;34(February (2)):537-47.
19. Rettig L, Haen SP, Bittermann AG, von Boehmer L, Curioni A, Kramer SD, et al. Particle size and activation threshold: a new dimension of danger signaling. Blood 2010;115(June (22)):4533-41.
20. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 2006;177(September (6)):3582-9.
21. Feltquate DM, Heaney S, Webster RG, Robinson HL, Different T. helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997;158(March (5)):2278-84.
22. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007;104(May (21)):8947-52.
23. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100(November (11)):2014-21.
24. Robson NC, McAlpine T, Knights AJ, Schnurr M, Shin A, Chen W, et al. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood 2010;116(July (2)):218-25.